Whistleblowing

Cytokinetics Investors Face Nov. 17 Deadline in Securities Suit Over Aficamten FDA Disclosures

Plaintiff firms allege the company misled shareholders about approval timing by submitting its aficamten application without a REMS after prior FDA safety discussions.